BNF:

Endocrine

Status:

Grey, Green

Decision Date:

None

Comments

Semglee - GREEN Preferred cost-effective brand. (Decision date - July 2023)

Lantus - GREEN 2nd line For patients needing cartridge/ vial. New patient should consider Semglee as the cost-effective brand. Existing patients on Lantus should continue on treatment until the next clinical review takes place, to assess if suitable for switching. (Decision date - July 2023)

Abasaglar - GREY New patient should consider Semglee as the cost-effective brand. Existing patients on Abasaglar should continue on treatment until the next clinical review takes place, to assess if suitable for switching. (Decision date - July 2023)

search again